Integrated analysis identifies GABRB3 as a biomarker in prostate cancer

BMC Medical Genomics

Table 1 Association of GABRB3 rs12591845 with OS and CSS in patients receiving ADT

Genotype	n of patients	OS					CSS
Genotype	n of patients	10-year OS	HR (95% CI)	P	HR (95% CI)^a	P^a	10-year CSS	HR (95% CI)	P	HR (95% CI)^a	P^a
AA	562	43.2	1.00		1.00		52.1	1.00		1.00
AG	64	61.3	0.58 (0.40–0.83)	0.003	0.53 (0.36–0.79)	0.002	68.9	0.55 (0.36–0.86)	0.008	0.57 (0.36–0.89)	0.013
GG	2	100.0	-	-	-	-	100.0	-	-	-	-
AG/GG	66	62.6	0.55 (0.38–0.80)	0.002	0.52 (0.35–0.77)	0.001	70.1	0.53 (0.35–0.82)	0.004	0.55 (0.35–0.86)	0.009
Trend^b			0.55 (0.38–0.79)	0.001	0.52 (0.35–0.76)	0.001		0.53 (0.35–0.81)	0.003	0.55 (0.35–0.85)	0.007

Abbreviations: OS: overall survival; CSS: cancer-specific survival; ADT: androgen deprivation therapy; HR: hazard ratio; CI: confidence interval
^a Adjustment for age, PSA at ADT initiation, clinical stage, Gleason score at diagnosis, PSA nadir, and time to PSA nadir
^b The trend P-values were calculated using a linear trend model with a continuous variable for the number of rare G alleles
-: not calculated due to small sample size

ISSN: 1755-8794